2014 Fireside Chat Speakers

  • Recommend
  • Tweet
  • Print
  • Email

Fireside chats feature candid discussions between biopharma CEOs, Wall Street analysts, and other industry experts. Hear about recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2014.

Leonard Bell, M.D.
Chief Executive Officer
Alexion Pharmaceuticals

February 11, 2014, 11:00 a.m. - 11:45 a.m. | Astor

Moderator: Eric Schmidt, PhD, Managing Director, Cowen Group

About the Speaker

Leonard Bell, M.D. is the Chief Executive Officer and principal founder of Alexion Pharmaceuticals. Under his continuous leadership since 1992, when he started the firm, Alexion has become a fast-growing and profitable global biopharmaceutical company, with more than 1,600 employees serving patients in 50 countries through fully integrated research, discovery, development, manufacturing and commercial capabilities.

Dr. Bell’s combination of scientific, clinical, regulatory and business skills have been central to Alexion’s accomplishments, from the early discovery and development of Soliris® (eculizumab) to the subsequent building and management of what is now a global commercial organization. Dr. Bell has emphasized strong growth and highly controlled use of financial resources as the Company continues its mission to develop life-transforming treatments for patients suffering with severe and life-threatening disorders that are also ultra-rare. Currently, under his leadership, Alexion’s commercial operations are driving the ongoing global launches of Soliris in PNH and aHUS, two life-threatening and ultra-rare disorders. At the same time, the company’s R&D organization is broadening and accelerating its development of new medical uses for Soliris, and is also developing additional highly innovative therapeutic candidates. In each of its ten current lead drug-development programs – which span medical specialties that include transplant, neurology, and metabolic disorders – the company is focused on providing a life-transforming, breakthrough treatment for patients with a severe and ultra-rare disease.

Prior to founding Alexion, Dr. Bell was an Attending Physician at Yale-New Haven Hospital and Assistant Professor of Medicine and Pathology at the Yale University School of Medicine, where he also received his M.D. degree. He remains on the faculty of the Yale University School of Medicine as an Adjunct Assistant Professor of Medicine and Pathology. Dr. Bell received his A.B. degree from Brown University.

About the Moderator

Eric Schmidt is a managing director and senior research analyst. He covers over 20 large-, mid-, and small-cap biotechnology stocks. Mr. Schmidt has been recognized in polls conducted by Alpha Magazine, Institutional Investor, Reuters, and The Wall Street Journal. Prior to joining Cowen and Company in 1998 he was a vice president covering the biotechnology sector for UBS Securities. He holds a BA in chemistry from the University of Pennsylvania and a Ph.D. in biochemistry from the Massachusetts Institute of Technology.

 

Belén Garijo, M.D.
President and CEO
Merck Serono

Tuesday, February 11, 2014, 12:00 p.m. - 12:45 p.m. | Astor

Moderator: Andrew Dickinson, Lazard

 

About the Speaker

Belén Garijo began her career at Abbott Laboratories as the Medical Director of its Spanish affiliate before moving to lead International Medical Affairs at the Abbott headquarters in Illinois, USA. In 1996 she returned to Spain to join Rhone Poulenc Rorer as the Director of the Oncology Business Unit, and in 2000, she was appointed to the position of Global Vice President Oncology with Aventis, based in New Jersey, USA.

In 2003, Dr. Garijo became the general Manager of Aventis Spain, and subsequently led the integration towards Sanofi-Aventis in 2004, staying on as General Manager of Sanofi-Aventis Spain. In 2006, she was appointed Senior Vice President Global Operations Europe, based in Paris, serving as a member of the Management Committee for the Sanofi-Aventis Group, and as a member of the Management Board for the Sanofi-Pasteur vaccines JV with MSD. In 2011, Dr. Garijo took on the additional role of Global Integration Leader for the Genzyme acquisition.

In late 2011, Dr. Garijo joined Merck Serono as Executive Vice President, Chief Operating Officer, serving as a member of the Pharmaceutical Executive Committee. In 2013, she was appointed President and CEO of Merck Serono.

Dr. Garijo is a medical doctor, specialized in clinical pharmacology (1984-1989). She obtained her degree in 1983 from the University of Alcalá de Henares.

About the Moderator

Andrew Dickinson joined Lazard's Healthcare Group in 2007 and is a Managing Director based in San Francisco. Mr. Dickinson has advised on transactions including the acquisition of ViroPharma for Shire, the acquisition of Onyx for Amgen, the acquisition of Human Genome Sciences for GSK, the sale of Anadys to Roche, the sale of Abraxis BioScience to Celgene, the sale of Oriel to Novartis/Sandoz, the acquisition of Noven for Hisamitsu, the sale of APP to Fresenius and the sale of Aspreva to Galenica. Prior to joining Lazard, Mr. Dickinson served as a Senior Legal Advisor to Gilead Sciences and as General Counsel and Vice President of Corporate Development at Myogen, Inc. While at Myogen, Mr. Dickinson managed the strategic process that culminated in Gilead's acquisition of Myogen (2006) and led complex licensing and partnership transactions, including a research and development collaboration with Novartis and a commercial development collaboration with GlaxoSmithKline. Prior to joining Myogen, Mr. Dickinson worked at Cooley Godward LLP and Kirkland & Ellis, LLP where he advised on public and private merger and acquisition transactions as well as debt and equity offerings, private equity fund formations and venture capital financings. University of Colorado, B.A. in Molecular, Cellular and Developmental Biology, Loyola University of Chicago, J.D. (cum laude)

 

Richard F. Pops
Chairman & Chief Executive Officer
Alkermes plc
 

Monday, February 10, 2014, 8:00 a.m. - 8:45 a.m | Astor

Moderator: David Gluckman, MD, Managing Director, Global Co-Head of Healthcare, Lazard
 

About the Speaker

Richard Pops serves as Chairman and Chief Executive Officer of Alkermes. He joined Alkermes as CEO in 1991. Under his leadership, Alkermes has grown from a privately held company with 25 employees to an international, publicly traded biopharmaceutical company with more than 1,200 employees and a portfolio of more than 20 commercial products. Mr. Pops currently serves on the Board of Directors of Neurocrine Biosciences, Acceleron Pharma, Epizyme, the Biotechnology Industry Organization (BIO) and the Pharmaceutical Research and Manufacturers of America (PhRMA).

About the Moderator

David Gluckman is Co-Head of Lazard’s Global Healthcare Group. He has been with the firm since 1998, providing strategic and financial advice to senior executives and boards of directors at leading healthcare and life sciences companies globally. Prior to joining Lazard, Dr. Gluckman was a practicing physician in Toronto, Canada. He founded a multi-specialty outpatient medical clinic, which he built into a thirty-physician practice and sold. Dr. Gluckman is a licentiate of the Medical Council of Canada and a member of the College of Physicians and Surgeons of Ontario. Dr. Gluckman had scientific and clinical research interests in the areas of lung transplantation and hepatobiliary tumors. 

 

David E.I. Pyott
Chairman of the Board & Chief Executive Officer
Allergan

Tuesday, February 11, 2014, 8:00 a.m. - 8:45 a.m. | Astor

Moderator: Seamus Fernandez, Managing Director, Major and Specialty Pharmaceuticals, Leerink Partners LLC

 

 

About the Speaker

David E.I. Pyott joined Allergan on January 1, 1998. During his tenure, Mr. Pyott has transformed Allergan from a small eye care business to a global specialty pharmaceutical and medical device company with leadership positions in six medical specialties. Allergan is currently the fastest growing global ophthalmic company and holds leadership positions in other specialty areas including neurosciences, medical aesthetics and medical dermatology.

Mr. Pyott has driven the growth of Allergan by fueling internal development through significant investment in Research & Development while also identifying and leveraging unique, synergistic external opportunities. Allergan’s investment in Research & Development has increased from less than $100 million in 1998 to approximately $1 billion in 2013. Most notably, from an external perspective, in March 2006, Allergan acquired Inamed Corp. for over $3 billion to create the world’s largest medical aesthetics company. In 2007, Allergan acquired Groupe Laboratories Cornéal in France. Most recently, in December 2012, Allergan acquired SkinMedica, Inc. and is now the U.S. leader in the growing “physician dispensed” topical aesthetics category. In addition, in March 2013, Allergan acquired MAP Pharmaceuticals for almost $1 billion for its inhaled migraine therapy technology, cementing Allergan’s leadership in the U.S. migraine market.

About the Moderator

Seamus Fernandez covers Major and Specialty Pharmaceuticals for Leerink Partners, and his stock picking ranks third among U.S. Pharmaceuticals analysts in 2012, according to ThomsonReuters StarMine. In the October 2008 and 2007 Institutional Investor poll, he was named “Best Up-and-Comer” covering the Pharmaceuticals/ Major sector.

Prior to joining Leerink in 2006, Mr. Fernandez had been a member of the major pharmaceuticals team at Cowen and Company, LLC. Before Cowen, Mr. Fernandez was a senior associate at the consulting firm, Putnam Associates, Inc. He began his career as a research associate at the University of Pennsylvania's Department of Neurosurgery where he conducted independent research using gene therapy and transgenic technology. His work was published in the Journal of Cerebral Blood Flow and Metabolism, Experimental Neurology and the Journal of Neurotrama.

Mr. Fernandez graduated from Williams College with a B.A. in Chemistry.

 

Christopher A. Viehbacher 
Chief Executive Officer, Sanofi
Chairman, Genzyme
President of the EFPIA, European Federation of Pharmaceutical Industries and Associations

Monday, February 10, 2014, 3:30 p.m. - 4:15 p.m. | Astor

Moderator: Anthony J. Gibney, Managing Director, Leerink Partners LLC
 

About the Speaker

Christopher A. Viehbacher, holds German and Canadian nationalities. He is a graduate of the Queens University (Ontario - Canada) and a certified public accountant. Since December 2008, he has held the position of Chief Executive Officer, Sanofi and is a Board member, in addition to being a member of the Strategy Committee. He is also Chairman of Genzyme, which Sanofi acquired in February 2011.

Christopher started his career in finance at PriceWaterhouseCoopers and joined GlaxoSmithKline (GSK) in 1988. Throughout the next 20 years with the company, he acquired broad international experience in Europe, in the United States and in Canada. His last position, before joining Sanofi was President, Pharmaceutical Operations North America. He was also a member of the board and Co-Chairman of the Portfolio Management Board.

Christopher was elected President of the EFPIA (European Federation of Pharmaceutical Industries and Associations) in June 2013 for a period of 2 years.

Christopher was Chairman of PhRMA in the United States (December 2010 – April 2012) and since February 2011 is Chair of the CEO Roundtable on Cancer. This association brings together employers across the United States to develop and implement workplace initiatives that reduce the risk of cancer, enable early diagnosis, facilitate better access to best-available treatments and hasten the discovery of novel and more effective diagnostic tools and anti-cancer therapies. Over 120 organisations are now members, covering 3 million employees.

In 2003, the French government acknowledged his commitment to public health and business by awarding Christopher a knight of the French Legion of Honor. He received the prestigious 2012 Pasteur Foundation Award, recognizing his leadership role within the pharmaceutical industry’s support of research & development and improving health of the 7 billion people around the world. Amongst other commitments, Christopher is also a member of International Business Council (WEF) and a member of the Board of Visitors of Fuqua School of Business, Duke University.

About the Moderator

Tony Gibney is a Managing Director at Leerink Partners in New York, where he has led the Firm’s East Coast biopharmaceuticals investment banking franchise since joining the Firm in mid-2009. In addition to having primary coverage responsibilities for East Coast biopharma companies, Tony also manages several relationships with larger European pharmaceutical companies. Prior to joining Leerink, Tony led the East Coast biotechnology and branded specialty pharmaceutical effort for the majority of his 10-year tenure at Merrill Lynch. Prior to Merrill, Tony was an analyst and associate in the Healthcare Investment Banking Group at Lehman Brothers from 1993 to 1999. Tony has executed over 100 M&A transactions, bookrun financings and other structured transactions over his 19-year, life sciences-focused investment banking career. Tony graduated with distinction from Yale University in 1993 with a B.A. in history and economics.